The administration of more than 50 meq of magnesium daily can produce the development of hypermagnesemia. This can provoke the formation of bladder and renal calculi. There is no known toxicity and the LD50 in animals are higher than 500 mg/kg in humans.T186 It is determined that magnesium silicate is not carcinogenic.L2614
Magnesium silicate is a compound of magnesium oxide and silicon. It is the magnesium salt of silicic acid containing an unspecified amount of water. The molecular formula can be expressed more clearly as MgSiO3.xH2O.T186 It is known as talc and it presents many uses in the cosmetic industry, food industry and pharmaceutical industry.L2603 Under the FDA, magnesium silicate is determined as a member of the substances generally recognized as safe (GRAS) to be used as an anticaking agent.L2605
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Succinylcholine | The therapeutic efficacy of Succinylcholine can be increased when used in combination with Magnesium silicate. |
| Metocurine iodide | The therapeutic efficacy of Metocurine iodide can be increased when used in combination with Magnesium silicate. |
| Gallamine triethiodide | The therapeutic efficacy of Gallamine triethiodide can be increased when used in combination with Magnesium silicate. |
| Cisatracurium | The therapeutic efficacy of Cisatracurium can be increased when used in combination with Magnesium silicate. |
| Rocuronium | The therapeutic efficacy of Rocuronium can be increased when used in combination with Magnesium silicate. |
| Atracurium besylate | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Magnesium silicate. |
| Doxacurium | The therapeutic efficacy of Doxacurium can be increased when used in combination with Magnesium silicate. |
| Mivacurium | The therapeutic efficacy of Mivacurium can be increased when used in combination with Magnesium silicate. |
| Decamethonium | The therapeutic efficacy of Decamethonium can be increased when used in combination with Magnesium silicate. |
| Metocurine | The therapeutic efficacy of Metocurine can be increased when used in combination with Magnesium silicate. |
| Pancuronium | The therapeutic efficacy of Pancuronium can be increased when used in combination with Magnesium silicate. |
| Pipecuronium | The therapeutic efficacy of Pipecuronium can be increased when used in combination with Magnesium silicate. |
| Vecuronium | The therapeutic efficacy of Vecuronium can be increased when used in combination with Magnesium silicate. |
| Rapacuronium | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Magnesium silicate. |
| Pyrantel | The therapeutic efficacy of Pyrantel can be increased when used in combination with Magnesium silicate. |
| Neosaxitoxin | The therapeutic efficacy of Neosaxitoxin can be increased when used in combination with Magnesium silicate. |
| Atracurium | The therapeutic efficacy of Atracurium can be increased when used in combination with Magnesium silicate. |
| Gallamine | The therapeutic efficacy of Gallamine can be increased when used in combination with Magnesium silicate. |
| Alcuronium | The therapeutic efficacy of Alcuronium can be increased when used in combination with Magnesium silicate. |
| Tubocurarine | The therapeutic efficacy of Tubocurarine can be increased when used in combination with Magnesium silicate. |
| Atazanavir | Magnesium silicate can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Bosutinib | Magnesium silicate can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cefditoren | The serum concentration of Cefditoren can be decreased when it is combined with Magnesium silicate. |
| Dabigatran etexilate | Magnesium silicate can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dabrafenib | Magnesium silicate can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dasatinib | Magnesium silicate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Delavirdine | Magnesium silicate can cause a decrease in the absorption of Delavirdine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Erlotinib | Magnesium silicate can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Gefitinib | Magnesium silicate can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Itraconazole | Magnesium silicate can cause a decrease in the absorption of Itraconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ledipasvir | Magnesium silicate can cause a decrease in the absorption of Ledipasvir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Methylphenidate | Magnesium silicate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Pazopanib | Magnesium silicate can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Riociguat | Magnesium silicate can cause a decrease in the absorption of Riociguat resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Calcitriol | The serum concentration of Magnesium silicate can be increased when it is combined with Calcitriol. |
| Calcifediol | The serum concentration of Magnesium silicate can be increased when it is combined with Calcifediol. |
| Cholecalciferol | The serum concentration of Magnesium silicate can be increased when it is combined with Cholecalciferol. |
| Paricalcitol | The serum concentration of Magnesium silicate can be increased when it is combined with Paricalcitol. |
| Dihydrotachysterol | The serum concentration of Magnesium silicate can be increased when it is combined with Dihydrotachysterol. |
| Alfacalcidol | The serum concentration of Magnesium silicate can be increased when it is combined with Alfacalcidol. |
| Seocalcitol | The serum concentration of Magnesium silicate can be increased when it is combined with Seocalcitol. |
| Inecalcitol | The serum concentration of Magnesium silicate can be increased when it is combined with Inecalcitol. |
| Becocalcidiol | The serum concentration of Magnesium silicate can be increased when it is combined with Becocalcidiol. |
| Eldecalcitol | The serum concentration of Magnesium silicate can be increased when it is combined with Eldecalcitol. |
| 1alpha,24S-Dihydroxyvitamin D2 | The serum concentration of Magnesium silicate can be increased when it is combined with 1alpha,24S-Dihydroxyvitamin D2. |
| Elocalcitol | The serum concentration of Magnesium silicate can be increased when it is combined with Elocalcitol. |
| Maxacalcitol | The serum concentration of Magnesium silicate can be increased when it is combined with Maxacalcitol. |
| Doxercalciferol | The serum concentration of Magnesium silicate can be increased when it is combined with Doxercalciferol. |
| Vitamin D | The serum concentration of Magnesium silicate can be increased when it is combined with Vitamin D. |
| 1alpha-Hydroxyvitamin D5 | The serum concentration of Magnesium silicate can be increased when it is combined with 1alpha-Hydroxyvitamin D5. |
| Previtamin D(3) | The serum concentration of Magnesium silicate can be increased when it is combined with Previtamin D(3). |
| Deferiprone | Magnesium silicate can cause a decrease in the absorption of Deferiprone resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dolutegravir | Magnesium silicate can cause a decrease in the absorption of Dolutegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Eltrombopag | Magnesium silicate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Levothyroxine | Magnesium silicate can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Tolevamer | The risk or severity of adverse effects can be increased when Tolevamer is combined with Magnesium silicate. |
| Bisacodyl | The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Magnesium silicate. |
| Captopril | Magnesium silicate can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cefpodoxime | The serum concentration of Cefpodoxime can be decreased when it is combined with Magnesium silicate. |
| Cefuroxime | The serum concentration of Cefuroxime can be decreased when it is combined with Magnesium silicate. |
| Chloroquine | Magnesium silicate can cause a decrease in the absorption of Chloroquine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Elvitegravir | Magnesium silicate can cause a decrease in the absorption of Elvitegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Gabapentin enacarbil | The serum concentration of Gabapentin enacarbil can be decreased when it is combined with Magnesium silicate. |
| Hyoscyamine | Magnesium silicate can cause a decrease in the absorption of Hyoscyamine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Rifampin | Magnesium silicate can cause a decrease in the absorption of Rifampicin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Mecamylamine | Magnesium silicate may decrease the excretion rate of Mecamylamine which could result in a higher serum level. |
| Memantine | Magnesium silicate may decrease the excretion rate of Memantine which could result in a higher serum level. |
| Penicillamine | Magnesium silicate can cause a decrease in the absorption of Penicillamine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Quinidine | Magnesium silicate may decrease the excretion rate of Quinidine which could result in a higher serum level. |
| Quinine | Magnesium silicate can cause a decrease in the absorption of Quinine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sotalol | The serum concentration of Sotalol can be decreased when it is combined with Magnesium silicate. |
| Sulpiride | The therapeutic efficacy of Sulpiride can be increased when used in combination with Magnesium silicate. |
| Deferasirox | Magnesium silicate can cause a decrease in the absorption of Deferasirox resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Allopurinol | The therapeutic efficacy of Allopurinol can be decreased when used in combination with Magnesium silicate. |
| Fexofenadine | Magnesium silicate can cause a decrease in the absorption of Fexofenadine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Raltegravir | Magnesium silicate can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Halofantrine | Magnesium silicate can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Misoprostol | The risk or severity of adverse effects can be increased when Magnesium silicate is combined with Misoprostol. |
| Mesalazine | Magnesium silicate can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Mycophenolic acid | The serum concentration of Mycophenolic acid can be decreased when it is combined with Magnesium silicate. |
| Cysteamine | The bioavailability of Cysteamine can be decreased when combined with Magnesium silicate. |
| Ketoconazole | Magnesium silicate can cause a decrease in the absorption of Ketoconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Moxifloxacin | Magnesium silicate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Grepafloxacin | Magnesium silicate can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Enoxacin | Magnesium silicate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Pefloxacin | Magnesium silicate can cause a decrease in the absorption of Pefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Trovafloxacin | Magnesium silicate can cause a decrease in the absorption of Trovafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Nalidixic acid | Magnesium silicate can cause a decrease in the absorption of Nalidixic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Rosoxacin | Magnesium silicate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cinoxacin | Magnesium silicate can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Lomefloxacin | Magnesium silicate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Gatifloxacin | Magnesium silicate can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Norfloxacin | Magnesium silicate can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Levofloxacin | Magnesium silicate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ofloxacin | Magnesium silicate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sparfloxacin | Magnesium silicate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Temafloxacin | Magnesium silicate can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Fleroxacin | Magnesium silicate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Technetium Tc-99m ciprofloxacin | Magnesium silicate can cause a decrease in the absorption of Technetium Tc-99m ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Garenoxacin | Magnesium silicate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |